Please assess the completion status of the following clinical trial:

Trial Title: Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 3 months~* HbA1c between 7.5-11.0% on monotherapy or~* HbA1c between 7.0-10.0% on dual therapy~* BMI maximum 45 kg/m2~Exclusion Criteria:~* Any clinically significant disease history in the opinion of the investigator~* Severe heart disease~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).